Browse by Series:

FDA Approval Sought in Multiple Myeloma, 2017 AACR Annual Meeting Highlights, and More

Patrick Borgen, MD
Published: Thursday, Apr 13, 2017



Patrick Borgen, MD, discusses an FDA approval sought for an agent in multiple myeloma, impressive phase III findings in non–small cell lung cancer, a change in USPSTF recommendations for PSA screening, and highlights from the 2017 AACR Annual Meeting.
Slider Left
Slider Right


Patrick Borgen, MD, discusses an FDA approval sought for an agent in multiple myeloma, impressive phase III findings in non–small cell lung cancer, a change in USPSTF recommendations for PSA screening, and highlights from the 2017 AACR Annual Meeting.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x